Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its…
Read More
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs)…
Read More
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101 Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day manufacturing…
Read More
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address…
Read More
Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells PHILADELPHIA--December 16, 2024 (BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human trophoblast stem cells (“hTSC”). By utilizing…
Read More
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases…
Read More
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) --PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with…
Read More
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing…
Read More
Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-totreat diseases, today announced the successful completion of a $25 million private financing round. This funding is…
Read More
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs)…
Read More
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer Mr. Korenberg is a seasoned executive with signifcant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs See more here
Read More
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases Financing led by Columbus Venture Partners, with participation by…
Read More
HueDx Transforms Point-of-Care Diagnostics with AI-Powered Smartphone Solutions HueDx's AI-powered platform improves point-of care diagnostics with enhanced accuracy, real-time data, and wider accessibility for rapid, reliable testing. See more here
Read More
Palvella Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts …
Read More
Wellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate See more here
Read More
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients See more here
Read More
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes See more here
Read More
Phrase Health Secures NIH SBIR Funding to Advance Innovative Analytics Solutions Phrase Health, Inc. secures $2M NIH SBIR grant to develop innovative EHR workflow management solutions, advancing patient care through data-driven, continuous improvement. See more here
Read More
Delve Health Partners with Strados Labs to Enhance Remote Patient Monitoring in Clinical Trials See more here
Read More
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 million of cash and…
Read More